|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Incidence and mortality of stomach cancer in China,2014显示文摘Objective: In this study,we aimed to estimate the updated incidence and mortality rate of stomach cancer based on the cancer registration data in 2014,collected by the National Central Cancer Registry of China(NCCRC).Methods: In 2017,339 registries' data were qualified based on the criteria of data quality control of the NCCRC.Cases of stomach cancer were retrieved from the national database.We estimated numbers of stomach cancer cases and deaths in China using age-specific rates and corresponding national population stratified by area,sex,agegroup(0,1–4,5–9,10–14,…,85+).Chinese standard population in 2000 and Segi's world population were applied for age-standardized incidence and mortality rates.Results: In 2014,410,400 new stomach cancer cases and 293,800 cancer-associated deaths were estimated to have occurred in China.The crude incidence rate of stomach cancer was 30.00/100,000,age-standardized incidence rates by Chinese standard population(ASIRC) and by world standard population(ASIRW) were 19.62/100,000 and19.51/100,000,respectively.The crude mortality rate of stomach cancer was 21.48/100,000,age-standardized mortality rates by Chinese(ASMRC) and by world standard population(ASMRW) were 13.44/100,000 and13.30/100,000,respectively.Incidence and mortality rates in rural areas were both higher than that in urban areas.Stomach cancer has a strong relationship with gender and age.The disease has occurred more frequently among men than women with a male to female ratio of 2.4 for ASIRC.After age group of 40-44 years,incidence rates are substantially higher in men than in women,same pattern was seen for age-specific mortality rates.Conclusions: There is still a heavy burden of stomach cancer in China.The incidence and mortality patterns of stomach cancer show substantial gender and regional disparities.Great effort is needed to provide more accessible health services,sufficient financial resources,and adequate cancer-care infrastructure for the Chinese population,especially for people living in rural areas. | Lei Yang Rongshou Zheng Ning Wang Yannan Yuan Shuo Liu Huichao Li Siwei Zhang Hongmei Zeng Wanqing Chen | 2018 | Chinese Journal of Cancer Research2018，30，3： | 114 |
| 2 | The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital.based multi.center study显示文摘Background: Stage at diagnosis and molecular subtype are important clinical factors associated with breast cancer patient survival. However, subgroup survival data from a large study sample are limited in China.To estimate the survival differences among patients with different stages and various subtypes of breast cancer, we conducted a hospital-based multi-center study on breast cancer in Beijing, China.Methods: All resident patients diagnosed with primary, invasive breast cancer between January 1,2006 and December 31,2010 from four selected hospitals in Beijing were included and followed up until December 31,2015. Hospitalbased data of stage at diagnosis, hormone receptor status, and selected clinical characteristics, including body mass index(BMI), menopausal status, histological grade, and histological type, were collected from the medical records of the study subjects. Overall survival(OS) and cancer-specific survival(CSS) were estimated. Cox proportional hazards models were employed to evaluate the associations of stage at diagnosis and molecular subtype with patient survival.Results: The 5-year OS and CSS rates for all patients were 89.4% and 90.3%. Survival varied by stage and molecular subtype. The 5-year OS rates for patients with stage I, Ⅱ, Ⅲ, and IV diseases were 96.5%, 91.6%, 74.8%, and 40.7%,respectively, and the corresponding estimates of 5-year CSS rates were 97.1%, 92.6%, 75.6%, and 42.7%, respectively.The 5-year OS rates for patients with luminal A, luminal B, HER2, and triple-negative subtypes of breast cancer were92.6%, 88.4%, 83.6%, and 82.9%, respectively, and the corresponding estimates of 5-year CSS rates were 93.2%, 89.1 %,85.4%, and 83.5%, respectively. Multivariate analysis showed that stage at diagnosis and molecular subtype were important prognostic factors for breast cancer.Conclusions: Survival of breast cancer patients varied significantly by stage and molecular subtype. Cancer screening is encouraged for the early detection and early diagnosis of breast cancer. More advanced therapies and health care policies are needed on HER2 and triple-negative subtypes. | Tingting Zuo Hongmei Zeng Huichao Li Shuo Liu Lei Yang Changfa Xia Rongshou Zheng Fei Ma Lifang Liu Ning Wang Lixue Xuan Wanqing Chen | 2017 | Chinese Journal of Cancer2017，36，11： | 18 |
| 3 | Investigation on the broadband electromagnetic wave absorption properties and mechanism of Co3O4- nanosheets/reduced-graphene-oxide composite显示文摘cobaltosic-oxide-nanosheets/reduced-graphene-oxide 合成(CoNSs@RGO ) 成功地作为一个小宽带电磁波吸收器被准备。样品厚度的效果和数量合成在吸收上补充说性质彻底地被调查到石蜡样品。由于公司 3 O 4, 很高,波浪吸收材料的 surface-to-volume 比率在吸收性质正在导致大改进。为 3.6 公里的厚度的 CoNSs@RGO 合成 was-45.15 dB 的最大的茶点损失,和有思考损失 below-10 dB 的最好的吸收带宽是有 2.9 公里的厚度的 7.14 GHz。另外,微波吸收的山峰与增加吸收涂层的厚度向低频率区域变了。电磁波吸收的机制被归因于阻抗象 RGO 的绝缘的松驰和极化一样匹配 CoNSs@RGO。比作以前报导的吸收材料, CoNSs@RGO 在高频率乐队为申请作为一个无足轻重的人和高度有效的吸收材料显示出更好的性能。 | Yi Ding Zheng Zhang Baohe Luo Qingliang Liao Shuo Liu Yichong Liu Yue Zhang | 2017 | Nano Research2017，10，3： | 16 |
| 4 | MiR-27a Promotes Hepatocellular Carcinoma Cell Proliferation Through Suppression of its Target Gene Peroxisome Proliferator-activated Receptor γ显示文摘 | Shuo Li Jing Li Bing-Yuan Fei Dan Shao Yue Pan Zhan-Hao MO Bao-Zhen Sun Dan Zhang Xiao Zheng Ming Zhang Xue-Wen Zhang Li Chen | 2015 | Chinese Medical Journal2015，，7： | 15 |
| 5 | Effect of Chinese Medicine on No or Slow Reflow after Percutaneous Coronary Intervention in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis显示文摘Objective:To systematic review the effect of Chinese medicine(CM)on no or slow reflow after percutaneous coronary intervention(PCI)in myocardial infarction(MI)patients.Methods:The Pub Med,EMBASE databases,Cochrane Central Register of Controlled Trials(CENTRAL),Web of Science,China National Knowledge Infrastructure(CNKI),Chinese BioMedical Literature Database(CBM),Wanfang Knowledge Service Platform(Wanfang Database)and Chinese Scientific Journal Database(VIP)were searched up to December 2017.Randomized controlled trials(RCTs)which evaluated the effect of CM therapies on no or slow reflow after PCI in MI patients were included.The primary outcome was the effect of reperfusion.Secondary outcomes were left ventricular ejection fraction,incidence of major adverse cardiovascular events and adverse effect.Results:Ten RCTs covering 814 patients were included.Two studies revealed that the incidence of no or slow reflow was less in Shenmai Injection(参麦注射液)group than in the control group measured by thrombolysis in myocardial infarction(TIMI)2(risk ratio=0.55,95%confidence interval 0.38 to 0.81,P=0.003,I^2=37%).Two studies indicated that Salvianolate Injection showed no additional benefit on no or slow reflow measured by corrected TIMI frame count compared with the conventional treatment(mean difference–4.24,95% confidence interval–13.03 to 4.54,P=0.34,I^2=86%).In addition,Tongxinluo Capsules(通心络胶囊),Danhong Injection(丹红注射液)and Xuesaitong Injection(血塞通注射液)may have the potential to reduce no or slow reflow measured during or after PCI in individual studies.Conclusions:Current evidence from RCTs are not sufficient to evaluate the effect of CM adjuvant therapies on no or slow reflow after PCI for MI patients.The included studies are limited by small sample size and unclear baseline conditions.Further rigorously designed researches and verification studies with sufficient number of patients are warranted. | ZHANG Xiao-yu SUN Yang YANG Xin-yu HU Jia-yuan ZHENG Rui CHEN Shi-qi LI Min LI Cheng-yu JIANG Yin LIU Shuo ZHAO Chen XING Yan-wei SHANG Hong-cai | 2020 | Chinese Journal of Integrative Medicine2020，26，3： | 11 |
| 6 | Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma显示文摘Background:Treatment guidelines for a variety of cancers have been increasingly used in clinical practice,and have resulted in major improvement in patient outcomes.However,recommended regimens(even first-line treat-ments)are clearly not ideal for every patients.In the present study,we used mini patient-derived xenograft(mini-PDX)and next-generation sequencing to develop personalized treatment in a patient with metastatic duodenal adenocarcinoma.Methods:Resected metachronous metastatic tumor tissues were implanted into SCID mice to determine the sensitivity to a variety of drug regimens.Mutation profiles were assessed using both DNA whole-exome sequencing(DNA-WES)and RNA sequencing.The results of the analyses were used to select optimal treatment for the patient with metastatic duodenal adenocarcinoma.Results:Assessment with mini-PDX models took only 7 days.The results showed high sensitivity to S-1 plus cis-platin,gemcitabine plus cisplatin and everolimus alone.The patient received gemcitabine plus cisplatin initially,but the treatment was terminated due to toxicity.The patient was then switched to treatment with S-1 alone.The overall disease-free survival was 34 months.DNA-WES and RNA sequencing identified KRAS mutation(A146T),TP53(C229Yfs*10)and RICTOR amplification in the metastatic duodenal adenocarcinoma.These findings provided further support to the results of the mini-PDX,and suggest mTOR inhibitors should be used if and when relapse eventually occurs in this patient.Conclusions:Mini-PDX model combined with WES/RNA sequencing can rapidly assess drug sensitivity in cancer patients and reveal key genetic alterations.Further research on this technology for personalized therapy in patients with refractory malignant tumors is warranted. | Peng Zhao Hui Chen Danyi Wen Shuo Mou Feifei Zhang Shusen Zheng | 2018 | Cancer Communications2018，38，1： | 11 |
| 7 | Outcomes in refractory diffuse large B-cell lymphoma:results fromamulticenter real-world study in China显示文摘Background:Diffuse large B-cell lymphoma(DLBCL)patients refractory to rituximab-based immunochemotherapy have a dismal prognosis.However,the definition of refractory DLBCL remains inconsistent and no large cohort study data is available from Asian countries.To validate the definition and outcomes of refractory DLBCL in China,we conducted a multicenter,retrospective cohort study.Methods:The REtrospective AnaLysis of Treatment REspoNse of refractory DLBCL(REAL-TREND)study was performed using real-world data from 8 centers in China.DLBCL patients with curative intent were included in the REAL-TREND dataset.Overall survival(OS)was estimated using the Kaplan-Meier method and compared by the log-rank test.Due to heterogeneity in response rates among different centers,the response rates of refractory patients were pooled using random-effect models.Multivariate survival analysis was performed using the Cox regression model.Results:A total of 2778 DLBCL patients diagnosed between January,2010 and December,2015 were enrolled to this study.After validating previous definitions,the SCHOLAR-1 study was most suitable to define refractory DLBCL.The estimated 5-year cumulative incidence of refractory patients was 20%(95% confidence Interval[CI]=18%-22%).After the determination of refractory disease,overall response rate and complete remission rate were 30%(95%CI=22%-38%)and 9%(95%CI=4%-15%),respectively.Patients with either no response to immunochemotherapy or relapse within 12 months after stem-cell transplantation had inferior survival with a median OS of 5.9 months(95%CI=5.5-7.1 months)and 2-year OS rate of 16%(95%CI=12%-20%).International prognostic index score 4-5(hazard ratio[HR]=2.22;95%CI=1.47-3.35),central nervous systemrelapse(HR=1.43;95%CI=1.04-1.97),and best response status(HR=2.68;95%CI=1.42-5.03 for partial remission.HR=5.97,95%CI=3.21-11.11 for stable disease/progressive disease)were independent unfavorable prognostic factors.Conclusions:This is the first large-scale Asian cohort study focusing on outcomes of refractory DLBCL.The definition of the SCHOLAR-1 study identifies patients with homogenously inferior survival,thus is appropriate to select refractory DLBCL.Due to poor clinical outcomes in the rituximab era,patients with refractory DLBCL may be potential candidates for novel treatment modalities. | Shuo Wang Li Wang Jianda Hu Wenbin Qian Xi Zhang Yu Hu Qi Zhu Bobin Chen Depei Wu Chung-Chou H.Chang Pengpeng Xu Xiaoyun Zheng Juying Wei Yao Liu Guohui Cui Yong Tang Yan Ma Haiwen Huang Hongmei Yi Weili Zhao | 2021 | Cancer Communications2021，41，3： | 10 |
| 8 | Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study显示文摘This study aimed to evaluate the efficacy of Chinese herbal medicine(CHM)in patients with severe/critical coronavirus disease 2019(COVID-19).In this retrospective study,data were collected from 662 patients with severe/critical COVID-19 who were admitted to a designated hospital to treat patients with severe COVID-19 in Wuhan before March 20,2020.All patients were divided into an exposed group(CHM users)and a control group(non-users).After propensity score matching in a 1:1 ratio,156 CHM users were matched by propensity score to 156 non-users.No significant differences in seven baseline clinical variables were found between the two groups of patients.All-cause mortality was reported in 13 CHM users who died and 36 non-users who died.After multivariate adjustment,the mortality risk of CHM users was reduced by 82.2%(odds ratio 0.178,95%CI 0.076–0.418;P<0.001)compared with the non-users.Secondly,age(odds ratio 1.053,95%CI 1.023–1.084;P<0.001)and the proportion of severe/critical patients(odds ratio 0.063,95%CI 0.028–0.143;P<0.001)were the risk factors of mortality.These results show that the use of CHM may reduce the mortality of patients with severe/critical COVID-19. | Guohua Chen Wen Su Jiayao Yang Dan Luo Ping Xia Wen Jia Xiuyang Li Chuan Wang Suping Lang Qingbin Meng Ying Zhang Yuhe Ke An Fan Shuo Yang Yujiao Zheng Xuepeng Fan Jie Qiao Fengmei Lian Li Wei Xiaolin Tong | 2020 | Frontiers of Medicine2020，14，6： | 10 |
| 9 | Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation:Preliminary experience显示文摘Background:Post-liver transplantation(LT)hepatocellular carcinoma(HCC)recurrence still occurs in approximately 20%of patients and drastically affects their survival.This study aimed to evaluate the efficacy of various treatments for recurrent HCC after LT in a Chinese population.Methods:A total of 64 HCC patients with tumor recurrence after LT were enrolled in this study.Univariate and multivariate analyses were performed to identify factors affecting post-recurrence survival.Results:Of the 64 patients with recurrent HCC after LT,those who received radical resection followed by nonsurgical therapy had a median overall survival(OS)of 20.9 months after HCC recurrence,significantly superior to patients who received only nonsurgical therapy(9.4 months)or best supportive care(2.4 months).The one-and two-year OS following recurrence was favorable for patients receiving radical resection followed by nonsurgical therapy(93.8%,52.6%),poor for patients receiving only nonsurgical therapy(30.8%,10.8%),and dismal for patients receiving best supportive care(0%,0%;overall P<0.001).Median OS in sorafenib-tolerant patients treated with lenvatinib was 19.5 months,far surpassing the patients that discontinued sorafenib or were treated with regorafenib after sorafenib failure(12 months,P<0.001).Compared with tacrolimus-based immunosuppressive therapy,OS was significantly increased with sirolimus-based therapy at one and two years after HCC recurrence(P=0.035).Multivariate analysis showed radical resection combined with nonsurgical therapy for recurrent HCC and sorafenib-lenvatinib sequential therapy were independent favorable factors for post-recurrence survival.Conclusions:Aggressive surgical intervention in well-selected patients significantly improves OS after recurrence.A multidisciplinary treatment approach is required to slow down disease progression for patients with unresectable recurrent HCC. | Zhe Yang Shuo Wang Xin-Yao Tian Qin-Fen Xie Li Zhuang Qi-Yong Li Cheng-Ze Chen Shu-Sen Zheng | 2020 | Hepatobiliary & Pancreatic Diseases International2020，19，4： | 9 |
| 10 | Promoter methylation of Wnt/β-Catenin signal inhibitor TMEM88 is associated with unfavorable prognosis of nonsmall cell lung cancer显示文摘Objective:Recent research has indicated that altered promoter methylation of oncogenes and tumor suppressor genes is an important mechanism in lung cancer development and progression.In this study,we investigated the association between promoter methylation of TMEM88,a possible inhibitor of the Wnt/β-Catenin signaling,and the survival of patients with nonsmall cell lung cancer(NSCLC).Methods:Twelve pairs of tumor and adjacent non-tumor samples were used for microarray analyses of DNA methylation and gene expression.For validation,more than two hundred additional samples were analyzed for methylation using bisulfite pyrosequencing and for gene expression using q RT-PCR.Then the cell function were tested by wound healing,transwell,CCK8 and cell cycle assay.Results:Our analysis of patient specimens showed that TMEM88 methylation was higher in NSCLC tumors(82.2%±10.3,P<0.01)compared with the adjacent normal tissues(65.9%±7.2).The survival analysis revealed that patients with high TMEM88methylation had a shorter overall survival(46 months)compared with patients with low TMEM88 methylation(>56 months;P=0.021).In addition,we found that demethylation treatment could inhibit tumor cell proliferation,migration,and invasion,which was supportive of an association between methylation and survival.Conclusions:Based on these consistent observations,we concluded that TMEM88 may play an important role in NSCLC progression and that promoter methylation of TMEM88 may serve as a biomarker for NSCLC prognosis and treatment. | Rongna Ma Nannan Feng Xiao Yu Hongyan Lin Xiaohong Zhang Oumin Shi Huan Zhang Shuo Zhang Lei Li Min Zheng Ming Gao Herbert Yu Biyun Qian | 2017 | Cancer Biology & Medicine2017，14，4： | 6 |
| 11 | Analysis of potential factors contributing to refusal of invasive strategy after ST-segment elevation myocardial infarction in China显示文摘Background:Reduced application of percutaneous coronary intervention(PCI)is associated with higher mortality rates after STsegment elevation myocardial infarction(STEMI).We aimed to evaluate potential factors contributing to the refusal of PCI in STEMI patients in China.Methods:We studied 957 patients diagnosed with STEMI in the emergency departments(EDs)of six public hospitals in China.The differences in baseline characteristics and 30-day outcome were investigated between patients who refused PCI and those who underwent PCI.Multivariable logistic regression was used to evaluate the potential factors associated with refusing PCI.Results:The potential factors contributing to refusing PCI were older than 65 years(odds ratio[OR]2.66,95%confidence interval[Cl]1.56-4.52,P<0.001),low body mass index(BMI)(OR 0.91,95%Cl 0.84-0.98,P=0.013),not being married(OR 0.29,95%Cl 0.17-0.49,P<0.001),history of myocardial infarction(MI)(OR 2.59,95%Cl 1.33-5.04,P=0.005),higher heart rate(HR)(OR 1.02,95%Cl 1.01-1.03,P=0.002),cardiac shock in the ED(OR 5.03,95%Cl 1.48-17.08,P=0.010),pre-hospital delay(>12 h)(OR 3.31,95%Cl 1.83-6.02,P<0.001)and not being hospitalized in a tertiary hospital(OR 0.45,95%Cl 0.27-0.75,P=0.002).Compared to men,women were older,were less often married,had a lower BMI and were less often hospitalized in tertiary hospitals.Conclusions:Patients who were older,had lower economic or social status,and had poorer health status were more likely to refuse PCI after STEMI.There was a sex difference in the potential predictors of refusing PCI.Targeted efforts should be made to improve the acceptance of PCI among patients with STEMI in China. | He Zhang Wen Zheng Shuo Wu Jing-Jing Ma Guang-Mei Wang Yong Li Jia-Qi Zheng Yuan Lyu Meng-Yang Xue Feng Xu Jia-Li Wang Yu-Guo Ghen | 2021 | Chinese Medical Journal2021，，5： | 6 |
| 12 | Tetramethylpyrazine prevents liver fibrotic injury in mice by targeting hepatocyte-derived and mitochondrial DNA-enriched extracellular vesicles显示文摘Liver fibrosis is the common consequence of almost all liver diseases and has become an urgent clinical problem without efficient therapies.Recent evidence has shown that hepatocytes-derived extracellular vesicles(EVs)play important roles in liver pathophysiology,but little is known about the role of damaged hepatocytes-derived EVs in hepatic stellate cell(HSC)activation and following fibrosis.Tetramethylpyrazine(TMP)from Ligusticum wallichii Franchat exhibits a broad spectrum of biological activities including liver protection.In this study,we investigated whether TMP exerted liver-protective action through regulating EV-dependent intercellular communication between hepatocytes and HSCs.Chronic liver injury was induced in mice by CCl_(4)(1.6 mg/kg,i.g.)twice a week for 8 weeks.In the last 4 weeks of CCl_(4) administration,mice were given TMP(40,80,160 mg·kg^(-1)·d^(-1),i.g.).Acute liver injury was induced in mice by injection of a single dose of CCl_(4)(0.8 mg/kg,i.p.).After injection,mice were treated with TMP(80 mg/kg)every 24 h.We showed that TMP treatment dramatically ameliorated CCl_(4)-induced oxidative stress and hepatic inflammation as well as acute or chronic liver fibrosis.In cultured mouse primary hepatocytes(MPHs),treatment with CCl_(4) or acetaminophen resulted in mitochondrial dysfunction,release of mitochondrial DNA(mtDNA)from injured hepatocytes to adjacent hepatocytes and HSCs through EVs,mediating hepatocyte damage and fibrogenic responses in activated HSCs;pretreatment of MPHs with TMP(25μM)prevented all these pathological effects.Transplanted serum EVs from TMP-treated mice prevented both initiation and progression of liver fibrosis caused by CCl_(4).Taken together,this study unravels the complex mechanisms underlying the protective effects of TMP against mtDNA-containing EV-mediated hepatocyte injury and HSC activation during liver injury,and provides critical evidence inspiring the development of TMP-based innovative therapeutic agents for the treatment of liver fibrosis. | Ya-jing Li Run-ping Liu Ming-ning Ding Qi Zheng Jian-zhi Wu Xiao-yong Xue Yi-qing Gu Bo-ning Ma Ya-jie Cai Shuo Li Sheng Lin Lu-yong Zhang Xiaojiaoyang Li | 2022 | Acta Pharmacologica Sinica2022，43，8： | 5 |
| 13 | Collagen derived species-specific peptides for distinguishing donkey-hide gelatin(Asini Corii Colla)显示文摘Objective:As an important food therapy product with traditional Chinese medicine(TCM) applications,donkey-hide gelatin(Asini Corii Colla,ACC) has been used for thousands of years.However,till now few effective strategy had been proposed to distinguish ACC from other animal hide gelatins,especially closely related horse-and mule-hide gelatins,which was an embarrassment of ACC quality control.Methods:Combined mass spectrometry and bioinformatic methods have been applied to identify and verify two ACC-specific peptides(Pep-1 and Pep-2) capable of distinguishing ACC from other closely related animal gelatins with high selectivity.Results:It confirmed that these two peptides could be not only used for distinguishing ACC from highly homologous horse-hide and mule-hide gelatins as well as other animal hide gelatins.Conclusion:The present study provides a simple method for species-specific peptides discovery,which can be used for assessing the quality of animal gelatin products,and ensure they are authenticable and traceable. | Shuo Cai Ke-xuan Zhao Meng-tong Jiang Shu-ying Han Yun-feng Zheng Xun Liu Ming Zhao Jin-ao Duan Rui Liu | 2021 | Chinese Herbal Medicines2021，13，2： | 5 |
| 14 | Analyses of a Glycine max Degradome Library Identify microRNA Targets and MicroRNAs that Trigger Secondary SiRNA Biogenesis显示文摘Plant microRNAs (miRNAs) regulate gene expression mainly by guiding cleavage of target mRNAs. In this study, a degradome library constructed from different soybean (Glycine max (L.) Merr.) tissues was deep-sequenced. 428 potential targets of small interfering RNAs and 25 novel miRNA families were identified. A total of 211 potential miRNA targets, including 174 conserved miRNA targets and 37 soybean-specific miRNA targets, were identified. Among them, 121 targets were first discovered in soybean. The signature distribution of soybean primary miRNAs (pri-miRNAs) showed that most pri-miRNAs had the characteristic pattern of Dicer processing. The biogenesis of TAS3 small interfering RNAs (siRNAs) was conserved in soybean, and nine Auxin Response Factors were identified as TAS3 siRNA targets. Twenty-three miRNA targets produced secondary small interfering RNAs (siRNAs) in soybean. These targets were guided by five miRNAs: gma-miR393, gma-miR1508, gma-miR1510, gma-miR1514, and novel-11. Multiple targets of these secondary siRNAs were detected. These 23 miRNA targets may be the putative novel TAS genes in soybean. Global identification of miRNA targets and potential novel TAS genes will contribute to research on the functions of miRNAs in soybean. | Zheng Hu Qiyan Jiang Zhiyong Ni Rui Chen Shuo Xu Hui Zhang | 2013 | Journal of Integrative Plant Biology2013，55，2： | 5 |
| 15 | Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China(RWE-PCSK study)显示文摘BACKGROUND The efficacy and safety of proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitors were confirmed by several clinical trials, but its effectiveness in routine clinical practice in China has not been evaluated. This study aims to describe the real world effectiveness of PCSK-9 inhibitors combined with statins compared with statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease(ASCVD).METHODS This is a multi-center observational study, enrolled patients from 32 hospitals who underwent percutaneous coronary intervention(PCI) from January to June in 2019. There are 453 patients treated with PCSK-9 inhibitors combined with statins in PCSK-9 inhibitor group and 2,610 patients treated with statins-based lipid lowering therapies in statins-based group. The lipid control rate and incidence of major adverse cardiovascular events(MACE) over six months were compared between two groups.A propensity score-matched(PSM) analysis was used to balance two groups on confounding factors. Survival analysis using Kaplan-Meier methods was applied for MACE.RESULTS In a total of 3,063 patients, 89.91% of patients had received moderate or high-intensity statins-based therapy before PCI, but only 9.47% of patients had low-density lipoprotein cholesterol(LDL-C) levels below 1.4 mmol/L at baseline. In the PSM selected patients, LDL-C level was reduced by 42.57% in PCSK-9 inhibitor group and 30.81%(P < 0.001) in statins-based group after six months. The proportion of LDL-C ≤ 1.0 mmol/L increased from 5.29% to 29.26% in PCSK-9 inhibitor group and 0.23% to 6.11% in statins-based group, and the proportion of LDL-C ≤ 1.4 mmol/L increased from 10.36% to 47.69% in PCSK-9 inhibitor group and 2.99% to 18.43% in statins-based group(P < 0.001 for both). There was no significant difference between PCSK-9 inhibitor and statins-based treatment in reducing the risk of MACE(hazard ratio = 2.52, 95% CI: 0.49-12.97, P = 0.250).CONCLUSIONS In the real world, PCSK-9 inhibitors combined with statins could significantly reduce LDL-C levels among patients with very high risk of ASCVD in China. The long-term clinical benefits for patients received PCSK-9 inhibitor to reduce the risk of MACE is still unclear and requires further study. | Yu-Qi LIU Dan-Dan LI Meng CHAI Hong-Liang CONG Xiao-Qiang CONG Jun DAI Rong-Pin DU Ming GAO Jin-Cheng GUO Yan-Qing GUO Xiao-Jian HONG Rong-Chong HUANG Feng-Shun JIA Jia-Yu LI Qing LI Jia-Mei LIU Xin-Ping LIU Yu-Guo LIU Hong-Gang NIE Bing SHAO Xiao-Yu SHEN Hai-Qing SONG Yi-Jun SONG Li-Jun WANG Shuo WANG Dong-Mei WU Jing XIA Zhi-Yong YANG Hong-Ying YU Hui ZHANG Tie-Mei ZHANG Ji-Yi ZHAO Liang-Chen ZHAO Ming-Qi ZHENG Yun-Dai CHEN | 2021 | Journal of Geriatric Cardiology2021，18，4： | 5 |
| 16 | A novel 4/6-type alpha-conotoxin VilA selectively inhibits nAchR α3β2 subtype显示文摘 | Liang Li Na Liu Rong Ding Shuo Wang Zhuguo Liu Haiying Li Xing Zheng Oiuyun Dai | 2015 | Acta Biochimica et Biophysica Sinica2015，47，12： | 4 |
| 17 | The combination of creatine kinase-myocardial band isoenzyme and point-of-care cardiac troponin/contemporary cardiac troponin for the early diagnosis of acute myocardial infarction显示文摘BACKGROUND:The early diagnosis of acute myocardial infarction(AMI)remains challenging,especially for institutions without the high-sensitive cardiac troponin(hs-c Tn)assay.Herein,we aim to assess the value of creatine kinase-myocardial band isoenzyme(CK-MB)combined with different cardiac troponin(c Tn)assays in AMI diagnosis.METHODS:This multicenter,observational study included 3,706 patients with acute chest pain from September 1,2015,to September 30,2017.We classified the participants into three groups according to the c Tn assays:the point-of-care c Tn(POC-c Tn)group,the contemporary c Tn(c-c Tn)group,and hs-c Tn group.The diagnostic value was quantified using sensitivity and the area under the curve(AUC).RESULTS:Compared to the single POC-c Tn/c-c Tn assays,combining CK-MB and POC-c Tn/c-c Tn increased the diagnostic sensitivity of AMI(56.1%vs.63.9%,P<0.001;82.7%vs.84.3%,P=0.025).In contrast,combining CK-MB and hs-c Tn did not change the sensitivity compared with hs-c Tn alone(95.0%vs.95.0%,P>0.999).In the subgroup analysis,the sensitivity of combining CKMB and c-c Tn increased with time from symptom onset<6 h compared with c-c Tn alone(72.8%vs.75.0%,P=0.046),while the sensitivity did not increase with time from symptom onset>6 h(97.5%vs.98.3%,P=0.317).The AUC of the combination of CK-MB and POC-c Tn significantly increased compared to the single POC-c Tn assay(0.776 vs.0.750,P=0.002).The AUC of the combined CKMB and c-c Tn/hs-c Tn assays did not significantly decrease compared with that of the single c-c Tn/hs-c Tn assays within 6 h.CONCLUSIONS:The combination of CK-MB and POC-c Tn or c-c Tn may be valuable for the early diagnosis of AMI,especially when hs-c Tn is not available. | Guang-mei Wang Yong Li Shuo Wu Wen Zheng Jing-jing Ma Feng Xu Jia-qi Zheng He Zhang Jia-li Wang Yu-guo Chen | 2022 | World Journal of Emergency Medicine2022，13，3： | 4 |
| 18 | Defect and interface engineering for electrochemical nitrogen reduction reaction under ambient conditions显示文摘Electrochemical nitrogen reduction reaction(e-NRR)under ambient conditions is an emerging strategy to tackle the hydrogen-and energy-intensive operations for traditional Haber-Bosch process in industrial ammonia(NH_(3))synthesis.However,the e-NRR performance is currently impeded by the inherent inertness of N_(2) molecules,the extremely slow kinetics and the overwhelming competition from the hydrogen evolution reaction(HER),all of which cause unsatisfied yield and ammonia selectivity(Faradaic efficiency,FE).Defect and interface engineering are capable of achieving novel physical and chemical properties as well as superior synergistic effects for various electrocatalysts.In this review,we first provide a general introduction to the NRR mechanism.We then focus on the recent progress in defect and interface engineering and summarize how defect and interface can be rationally designed and functioned in NRR catalysts.Particularly,the origin of superior NRR catalytic activity by applying these approaches was discussed from both theoretical and experimental perspectives.Finally,the remaining challenges and future perspectives in this emerging area are highlighted.It is expected that this review will shed some light on designing NRR electrocatalysts with excellent activity,selectivity and stability. | Dongxue Guo Shuo Wang Jun Xu Wenjun Zheng Danhong Wang | 2022 | Journal of Energy Chemistry2022，31，2： | 4 |
| 19 | Status epilepticus associated with Mycoplasma pneumoniae encephalitis in children: good prognosis following early diagnosis and treatment显示文摘Mycoplasma pneumoniae is a common pathogen that leads to respiratory tract infections in children, often causing immune-related injuries in multiple other organs and tissues. The involvement of central nervous system has been reported in 5% to 7% of patients with M. pneumoniae infection.[1] The clinical manifestations of M. pneumoniae encephalitis are highly heterogeneous, and more than half of patients experience seizures during the acute phase, with status epilepticus occurring in severe cases.[2] | Shuo Feng Jin-Xiao Chen Ping Zheng Jian-Zhao Zhang Zhi-Jie Gao Ying-Ying Mao Xin-Na Ji Shu-Hua Chen Hong-Mei Sun Qian Chen | 2019 | Chinese Medical Journal2019，，12： | 4 |
| 20 | Design of wide-range energy material beamline at the Shanghai Synchrotron Radiation Facility显示文摘We report the design of a wide-range energy material beamline(E-line) with multiple experimental techniques at the Shanghai Synchrotron Radiation Facility.The undulators consisted of an elliptically polarizing undulator and in-vacuum undulator that generate the soft and hard X-rays, respectively. The beamline covered a wide energy range from 130 to 18 ke V with both a high photon flux([ 10^(12) phs/s with exit silt 30 lm in soft X-ray and [ 5 9 10^(12) phs/s in hard X-ray within 0.1%BW bandwidth) and promising resolving power(maximum E/DE [ 15,000 in soft X-ray with exit silt 30 lm and [6000 in hard X-ray). Moreover, the beam spots from the soft and hard X-rays were focused to the same sample position with a high overlap ratio, so that the surfaces, interfaces, and bulk properties were characterized in situ by changing the probing depth. | Zhen-Hua Chen Fan-Fei Sun Ying Zou Fei Song Shuo Zhang Zheng Jiang Yong Wang Ren-Zhong Tai | 2018 | Nuclear Science and Techniques2018，29，2： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员